192 related articles for article (PubMed ID: 27118859)
41. TGF-β1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis.
Kong J; Qiu Y; Li Y; Zhang H; Wang W
Biopharm Drug Dispos; 2019 Feb; 40(2):70-80. PubMed ID: 30698830
[TBL] [Abstract][Full Text] [Related]
42. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
43. Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.
Wang J; Bruin MAC; Gan C; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
Int J Pharm; 2020 May; 581():119277. PubMed ID: 32234426
[TBL] [Abstract][Full Text] [Related]
44. Hepatic and intestinal CYP3A expression and activity in broilers.
Osselaere A; De Bock L; Eeckhaut V; De Backer P; Van Bocxlaer J; Boussery K; Croubels S
J Vet Pharmacol Ther; 2013 Dec; 36(6):588-93. PubMed ID: 23330986
[TBL] [Abstract][Full Text] [Related]
45. Potential Pharmacokinetic Effect of Chicken Xenobiotic Receptor Activator on Sulfadiazine: Involvement of P-glycoprotein Induction.
Li M; Xu Z; Lu W; Wang L; Zhang Y
Antibiotics (Basel); 2022 Jul; 11(8):. PubMed ID: 35892397
[TBL] [Abstract][Full Text] [Related]
46. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
[TBL] [Abstract][Full Text] [Related]
47. P-Glycoprotein and Breast Cancer Resistance Protein in Canine Inflammatory and Noninflammatory Grade III Mammary Carcinomas.
Levi M; Peña L; Alonso-Díez A; Brunetti B; Muscatello LV; Benazzi C; Pérez-Alenza MD; Sarli G
Vet Pathol; 2019 Nov; 56(6):840-847. PubMed ID: 31526115
[TBL] [Abstract][Full Text] [Related]
48. Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
Asaumi R; Nunoya KI; Yamaura Y; Taskar KS; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):919-933. PubMed ID: 35570332
[TBL] [Abstract][Full Text] [Related]
49. Intestinal absorption mechanisms of 2'-deoxy-2'-β-fluoro-4'-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein.
Liu Y; Liu B; Zhang Y; Peng Y; Huang C; Wang N; Jiang J; Wang Q; Chang J
Eur J Pharm Sci; 2017 Jul; 105():150-158. PubMed ID: 28487144
[TBL] [Abstract][Full Text] [Related]
50. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
[TBL] [Abstract][Full Text] [Related]
51. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
[TBL] [Abstract][Full Text] [Related]
52. Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples.
Canaparo R; Nordmark A; Finnström N; Lundgren S; Seidegård J; Jeppsson B; Edwards RJ; Boobis AR; Rane A
Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):240-8. PubMed ID: 17371528
[TBL] [Abstract][Full Text] [Related]
53. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
54. Uric acid transporters BCRP and MRP4 involved in chickens uric acid excretion.
Ding X; Li M; Peng C; Wang Z; Qian S; Ma Y; Fang T; Feng S; Li Y; Wang X; Li J; Wu J
BMC Vet Res; 2019 May; 15(1):180. PubMed ID: 31146764
[TBL] [Abstract][Full Text] [Related]
55. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
56. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
57. Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine.
Xie QS; Zhang JX; Liu M; Liu PH; Wang ZJ; Zhu L; Jiang L; Jin MM; Liu XN; Liu L; Liu XD
Acta Pharmacol Sin; 2021 Mar; 42(3):470-481. PubMed ID: 32555444
[TBL] [Abstract][Full Text] [Related]
58. Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine.
Brueck S; Bruckmueller H; Wegner D; Busch D; Martin P; Oswald S; Cascorbi I; Siegmund W
Mol Pharm; 2019 Sep; 16(9):3823-3830. PubMed ID: 31361500
[TBL] [Abstract][Full Text] [Related]
59. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
60. Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
Wang Z; Yang H; Xu J; Zhao K; Chen Y; Liang L; Li P; Chen N; Geng D; Zhang X; Liu X; Liu L
Drug Metab Dispos; 2019 Oct; 47(10):1066-1079. PubMed ID: 31399507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]